Clowes Howard 4

4 · PLUS THERAPEUTICS, INC. · Filed May 18, 2026

AI-generated summary of this filing

Updated May 18, 2026

Plus Therapeutics (PSTV) Director Clowes Howard Receives RSU Award

What Happened

Director Clowes Howard was granted two awards of Restricted Stock Units (RSUs) on 2026-05-14 totaling 7,372 RSUs (3,686 + 3,686). Each RSU is a contingent right to one share of Plus Therapeutics common stock; the awards show a $0 acquisition price (derivative awards), not an open‑market purchase or sale. This is an equity compensation grant rather than a cash transaction.

Key Details

Transaction date: May 14, 2026; Form 4 filed May 18, 2026 (timely — within two business days).
Type/code: A = Award/Grant (derivative RSUs), reported at $0.00 per RSU.
Quantity: 7,372 RSUs total (3,686 + 3,686).
Shares owned after transaction: Not specified in the provided filing.
Notable footnotes:
- F1: Each RSU converts to one share when vested; the RSUs vest ratably over four quarters in equal 1/4 increments, with the first 1/4 vesting on July 1, 2026 and the remainder quarterly thereafter.
- F2: Describes an options vesting schedule (monthly over 12 months, with full vesting at the 2027 Annual Meeting) — this applies to options referenced in the filing footnotes but no option exercise/sale was reported in the transactions above.

Context

RSU grants are a form of compensation and become actual shares only as they vest; they are not an immediate purchase signal. Because these awards vest over time, their conversion to tradable shares depends on continued service/vesting conditions noted in F1 (and F2 for any option grants). No sale or purchase of shares occurred in this filing.

Form 4

Period: 2026-05-14

Director

Transactions

Award
Restricted Stock Units
[F1]
2026-05-14+3,686→ 3,686 total
Exercise: $0.00→ Common Stock (3,686 underlying)
Award
Stock Option (Right to Buy)
[F2]
2026-05-14+3,686→ 3,686 total
Exercise: $5.76Exp: 2036-05-14→ Common Stock (3,686 underlying)

Footnotes (2)

[F1]Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs awarded vest ratably over four quarters in substantially equal 1/4th increments, commencing with 1/4th vesting on July 1, 2026 and the remainder vesting quarterly thereafter.
[F2]The options vest monthly over 12 months from the grant date in substantially equal monthly increments, provided that the options vest in full on the Issuer's 2027 Annual Stockholder Meeting, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date or, if earlier, such annual meeting.

Signature

Andrew Sims, as attorney-in-fact|2026-05-18

1 file